nach oben

Erschienen in:

01.07.2014 | Original Article

Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)

verfasst von: Rathi N. Pillai, Joseph Aisner, Suzanne E. Dahlberg, John S. Rogers, Robert S. DiPaola, Seena Aisner, Suresh S. Ramalingam, Joan H. Schiller

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with recurrent small-cell lung cancer (SCLC) have dismal outcomes. The failure of salvage therapy is due to the possible development of resistance mechanisms, such as the upregulation of the anti-apoptosis protein, Bcl-2. We conducted a phase II study to evaluate if modulation of Bcl-2 with 13-cis-retinoic acid (13-CRA) and interferon alpha could improve response rates when combined with paclitaxel in patients with recurrent SCLC.

Methods

Patients with recurrent SCLC and measurable disease were treated with interferon alpha at 6 million units/m² subcutaneously and 13-CRA 1 mg/kg orally on days 1 and 2 and paclitaxel 75 mg/m² intravenously on day 2 of each week for 6 weeks of an 8-week treatment cycle. Treatment was continued until disease progression, development of unacceptable toxicity, or withdrawal of consent. The primary endpoint was response rate with secondary endpoints of progression-free survival (PFS) and overall survival (OS). Bcl-2 levels were assessed in peripheral blood mononuclear cells (PBMCs).

Results

Thirty-seven patients were enrolled; 34 were included in the intention-to-treat analysis as 3 patients were ineligible for the study. There were 3 partial responses (9 %), and 5 patients had stable disease (15 %) as best response. The median PFS was 2 months, and median OS was 6.2 months. Although mean Bcl-2 protein levels decreased with therapy in PBMCs, there was no association between Bcl-2 levels and response rate or survival.

Conclusion

Despite sound pre-clinical evidence, the addition of 13-CRA and interferon alpha to paclitaxel did not improve outcomes for recurrent SCLC.

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30PubMedCrossRef

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539–4544PubMedCrossRef

Ettinger DS, Aisner J (2006) Changing face of small-cell lung cancer: real and artifact. J Clin Oncol 24(28):4526–4527PubMedCrossRef

Abrams J, Doyle LA, Aisner J (1988) Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 15(3):261–277PubMed

Aisner J, Alberto P, Bitran J, Comis R, Daniels J, Hansen H et al (1983) Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 67(1):37–43PubMed

Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R et al (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 20(24):4665–4672PubMedCrossRef

Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P et al (2008) Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 99(3):442–447PubMedCentralPubMedCrossRef

von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17(2):658–667

Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S et al (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10(8):1225–1229PubMed

10.

Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8(10):1613–1617PubMed

11.

Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE (1998) A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77(2):347–351PubMedCentralPubMedCrossRef

12.

Cheng S, Evans WK, Stys-Norman D, Shepherd FA (2007) Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol. 2(4):348–354PubMedCrossRef

13.

Reed JC (1995) Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett 82–83:155–158PubMedCrossRef

14.

McConkey DJ, Greene G, Pettaway CA (1996) Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56(24):5594–5599PubMed

15.

Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC et al (1995) Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93(2):147–155PubMedCrossRef

16.

McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT et al (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52(24):6940–6944PubMed

17.

Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55(19):4438–4445PubMed

18.

Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E et al (1996) Expression of bcl-2—protein in small cell lung cancer. Lung Cancer 15(1):31–40PubMedCrossRef

19.

Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G (1994) Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145(5):1036–1040PubMedCentralPubMed

20.

Sartorius UA, Krammer PH (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97(5):584–592PubMedCrossRef

21.

Smith MA, Parkinson DR, Cheson BD, Friedman MA (1992) Retinoids in cancer therapy. J Clin Oncol 10(5):839–864PubMed

22.

Dahiya R, Boyle B, Park HD, Kurhanewicz J, Macdonald JM, Narayan P (1994) 13-cis-retinoic acid-mediated growth inhibition of DU-145 human prostate cancer cells. Biochem Mol Biol Int 32(1):1–12PubMed

23.

Hu ZB, Minden MD, McCulloch EA (1996) Regulation of the synthesis of bcl-2 protein by growth factors. Leukemia 10(12):1925–1929PubMed

24.

Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM et al (1992) 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84(4):235–241PubMedCrossRef

25.

Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK et al (1992) 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84(4):241–245PubMedCrossRef

26.

DiPaola RS, Weiss RE, Cummings KB, Kong FM, Jirtle RL, Anscher M et al (1997) Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen. Clin Cancer Res 3(11):1999–2004PubMed

27.

DiPaola RS, Aisner J (1999) Overcoming bcl-2- and p53-mediated resistance in prostate cancer. Semin Oncol 26(1 Suppl 2):112–116PubMed

28.

DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, Patel J et al (1999) Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol 17(7):2213–2218PubMed

29.

Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M et al (2008) Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 26(6):870–876PubMedCentralPubMedCrossRef

30.

Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ et al (2011) A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 6(10):1757–1760PubMedCentralPubMedCrossRef

31.

Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N et al (2011) A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 74(3):481–485PubMedCentralPubMedCrossRef

32.

Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR et al (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18(11):3163–3169PubMedCentralPubMedCrossRef

Titel: Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)
verfasst von: Rathi N. Pillai
Joseph Aisner
Suzanne E. Dahlberg
John S. Rogers
Robert S. DiPaola
Seena Aisner
Suresh S. Ramalingam
Joan H. Schiller
Publikationsdatum: 01.07.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2014
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2427-7

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)